Reckitt Benckiser has agreed to pay $3.5 million to settle a class action over its Nurofen range
Bannister Law announced that it has reached an agreement with Reckitt Benckiser over the Keith Hardy vs Reckitt Benckiser (Australia) class action, settling on an amount of $3.5 million plus the applicants’ legal costs.
“Under the terms of the Settlement Deed, the Respondent will pay the sum of $3.5 million dollars into a settlement fund for distribution to eligible group members,” Bannister Law stated.
“This fund will be administered by an independent third party over a period of four months.”
This means that any person who purchased a product from the Nurofen Specific Pain Range between 2011 and 2015 may register a claim for compensation from the settlement fund.
Bannister Law says it anticipates Settlement Notices will shortly be published in newspapers around the country, encouraging such consumers to come forward and register.
Bannister Law encouraged all individuals who believed they had a claim to register via their website.
Reckitt Benckiser (Australia) apologised in a statement to consumers who might have been misled by the range’s packaging.
Late last year, the company was subject to a record fine of $6 million for making misleading representations about its Nurofen Specific Pain products.
This was a revised penalty, up from $1.7 million, after the Australian Competition and Consumer Commission appealed the original fine.
In December 2015, following admissions by Reckitt Benckiser, the Full Federal Court found that the company engaged in misleading or deceptive conduct between 2011 and 2015, by making representations on its website and product packaging that Nurofen Specific Pain products were each formulated to treat a specific type of pain, when this was not the case.
Each Nurofen Specific Pain product contains the same active ingredient (ibuprofen lysine 342mg).